Unknown

Dataset Information

0

Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models.


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to a late diagnosis and poor response to available treatments. There is a need to identify complementary treatment strategies that will enhance the efficacy and reduce the toxicity of currently used therapeutic approaches. We investigated the ability of a known ROS inducer, piperlongumine (PL), to complement the modest anti-cancer effects of the approved chemotherapeutic agent gemcitabine (GEM) in PDAC cells in vitro and in vivo. PDAC cells treated with PL + GEM showed reduced cell viability, clonogenic survival, and growth on Matrigel compared to control and individually-treated cells. Nude mice bearing orthotopically implanted MIA PaCa-2 cells treated with both PL (5 mg/kg) and GEM (25 mg/kg) had significantly lower tumor weight and volume compared to control and single agent-treated mice. RNA sequencing (RNA-Seq) revealed that PL + GEM resulted in significant changes in p53-responsive genes that play a role in cell death, cell cycle, oxidative stress, and DNA repair pathways. Cell culture assays confirmed PL + GEM results in elevated ROS levels, arrests the cell cycle in the G0/G1 phase, and induces PDAC cell death. We propose a mechanism for the complementary anti-tumor effects of PL and GEM in PDAC cells through elevation of ROS and transcription of cell cycle arrest and cell death-associated genes. Collectively, our results suggest that PL has potential to be combined with GEM to more effectively treat PDAC.

SUBMITTER: Mohammad J 

PROVIDER: S-EPMC5828188 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Piperlongumine potentiates the effects of gemcitabine in <i>in vitro</i> and <i>in vivo</i> human pancreatic cancer models.

Mohammad Jiyan J   Dhillon Harsharan H   Chikara Shireen S   Mamidi Sujan S   Sreedasyam Avinash A   Chittem Kishore K   Orr Megan M   Wilkinson John C JC   Reindl Katie M KM  

Oncotarget 20171223 12


Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to a late diagnosis and poor response to available treatments. There is a need to identify complementary treatment strategies that will enhance the efficacy and reduce the toxicity of currently used therapeutic approaches. We investigated the ability of a known ROS inducer, piperlongumine (PL), to complement the modest anti-cancer effects of the approved chemotherapeutic agent gemcitabine (GEM) in PDAC cells <i>in vitro<  ...[more]

Similar Datasets

| S-EPMC4621909 | biostudies-other
| S-EPMC4692438 | biostudies-literature
| S-EPMC5696795 | biostudies-literature
| S-EPMC5130026 | biostudies-literature
| S-EPMC4294371 | biostudies-other
| S-EPMC5364111 | biostudies-literature
| S-EPMC5800424 | biostudies-literature
| S-EPMC6263055 | biostudies-literature
| S-EPMC8330535 | biostudies-literature
| S-EPMC4102943 | biostudies-literature